SCHEMBL22896923

SCHEMBL22896923

Cn1cc(C(=O)NC(Cc2ccccc2)C(O)C(N)=O)c(-c2cnccn2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGL P06737 1/20 0.41
▸ DCAF1 Q9Y4B6 1/20 0.40
▸ CNR1 P21554 3/20 0.40
▸ CNR2 P34972 3/20 0.40
▸ CCR1 P32246 4/20 0.38
▸ CTSL P07711 1/20 0.38
▸ LONP1 P36776 4/20 0.37
▸ PSMB11 A5LHX3 3/20 0.37
▸ PSMA7 O14818 3/20 0.37
▸ PSMB1 P20618 3/20 0.37
▸ PSMA1 P25786 3/20 0.37
▸ PSMA2 P25787 3/20 0.37
▸ PSMA3 P25788 3/20 0.37
▸ PSMA4 P25789 3/20 0.37
▸ PSMB8 P28062 3/20 0.37
▸ PSMB9 P28065 3/20 0.37
▸ PSMA5 P28066 3/20 0.37
▸ PSMB4 P28070 3/20 0.37
▸ PSMB6 P28072 3/20 0.37
▸ PSMB5 P28074 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20027817 1.00 PYGL (0.41) PYGLDCAF1CNR1CNR2CCR1
SCHEMBL21854099 0.85 CAPN1 (0.52) CAPN1
SCHEMBL20027883 0.85 CAPN1 (0.52) CAPN1
SCHEMBL24444088 0.83 CCR1 (0.40) PYGLCNR1CNR2CCR1CTSL
SCHEMBL24444089 0.83 CCR1 (0.40) PYGLCNR1CNR2CCR1CTSL
SCHEMBL20027617 0.82 PYGL (0.43) PYGLDCAF1CNR1CNR2CCR1
SCHEMBL20028150 0.80 DCAF1 (0.41) PYGLDCAF1CNR1CNR2CCR1
SCHEMBL20028606 0.80 PYGL (0.43) PYGLDCAF1CNR1CNR2CCR1
SCHEMBL20027914 0.80 DCAF1 (0.48) PYGLDCAF1CA12CA1CA2
SCHEMBL22885966 0.80 CTSV (0.48) PYGLDCAF1CNR1CNR2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 PYGL 925/4885DCAF1 3091/4885CNR1 3073/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 PYGL 668/4885DCAF1 3598/4885CNR1 2961/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 PYGL 925/4885DCAF1 3091/4885CNR1 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback